Impact of EGFR Mutations on Survival and Clinical Response in Non‐Small Cell Lung Cancer in a Tertiary Care Hospital

Documenti analoghi

• Investigation of the Molecular Mechanisms of Paraoxonase‐2 Mediated Radiotherapy and Chemotherapy Resistance in Oral Squamous Cell Carcinoma
  di: Mehta Vedant Kamal, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients
  di: Kun Wang, et al.
  Pubblicazione: (2025)
• Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
  di: Tvisha Devireddy, et al.
  Pubblicazione: (2025)
• Gastric Signet Ring Cell Carcinoma: Tumor Microenvironment Reprogramming and Novel Therapeutic Targets With Emphasis on GRIN2D
  di: Dipali Raju, et al.
  Pubblicazione: (2025)
• Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
  di: Shang‐Gin Wu, et al.
  Pubblicazione: (2024)